51Ventures Investment Update: AxoLongevity

We’re excited to share that 51Ventures has invested in AxoLongevity, a fast-moving performance and longevity company building one of the most advanced personalized health platforms in Europe.

AxoLongevity combines biomarkers, wearables, high-performance data, and medical insights into a single platform that helps users visualize their health, detect risk earlier, and optimize long-term performance and vitality.

Why we’re excited

AxoLongevity is led by a world-class founding and medical team:

• Andrew McCarthy — CEO & Founder
  3x founder. Previously built Aikito to $25M GMV (backed by Northzone & Bloomberg). Deep experience across consumer and prop-tech, with academic roots at NYU, LSE, and Ibero.

• Dr. Niko Mihic — Chief Medical Officer
  World-renowned Real Madrid Medical Advisor & Longevity Authority with experience across La Liga, Premier League, NBA, NFL, British Air Force, and SAS.

• Andy Walshe, PhD — Executive Longevity Advisor
  Former Red Bull High Performance Chief with experience across Formula 1, MotoGP, NASA, Navy, Google, NFL, NHL, MLB, and more.

Momentum that matters

• Product shipped — platform live (website + iOS app + biomarker engine).

• 35+ active beta users already paying and engaging with the product.

• 8,000+ waitlist signups, with CPL dropping from $20 → $3.

• Labs active in 4 markets: Spain, UK, Germany, Netherlands — with access to 10 more.

• Ambassador network of 30 influencers representing a combined 10M+ followers, with 30 more in discussions.

• Launched across 4 markets in only 9 weeks, with rapid iteration based on real-time data.

Axo’s early execution mirrors the fast-scaling U.S. subscription models in longevity and performance — but with a European wedge where demand and digital adoption are primed.

The opportunity ahead

• Europe’s digital health market reached €66B in 2023 and is growing at 22% CAGR.

• Axo’s targeted €5B high-performance TAM supports €250–€350M ARR potential within three years.

• The platform captures a full picture of health with 100+ biomarkers, wearables integrations (Garmin, Apple, Oura, Whoop), historical medical data via EHDS, and anonymized performance insights from its clinical team.

Axo is becoming the bridge between vitality and science, delivering prevention, performance, and longevity in a single consumer experience.

Learn more: axolongevity.com